Background: Lung cancer is often diagnosed late when treatment options are limited. The goal of screening for lung cancer with low dose CT is to diagnose at an earlier stage, when more treatment options including potentially curative surgery are available. Our Regional Cancer Center partnered with Thoracic Surgery to develop a nurse practitioner led screening program to ensure that eligible patients are screened following current guidelines. The process is cumbersome for providers as the reimbursement process requires specific, time consuming documentation which may prevent providers from offering screening. There is a high rate of incidental findings which providers may be uncomfortable managing. Potential exists for patients to be lost to followup. Screening for cancer is also anxiety provoking for patients. A centralized program run by a NP with an oncology background can alleviate these issues while providing quality evidence based care. Vision: Advance practice providers in oncology are uniquely positioned to provide lung cancer screening. Our holistic approach to care, focusing on disease prevention and health promotion allows us to guide the patient through a potentially stressful screening process. The Thoracic NP meets with patients for the shared decision making visit and orders the CT. The NP directly follows up with patients for results, and manages all incidental findings, subsequent diagnostic procedures, referrals to specialty care while ensuring close communication with referring providers. The NP has access to weekly multidisciplinary thoracic conference to discuss significant findings and provides all longitudinal follow up regarding lung cancer screening. Programmatic Challenges: Lung cancer screening programs face a variety of challenges requiring collaboration of multiple departments including billing, registration, radiology, information technology, and marketing. Extensive PCP education is required on screening guidelines, including buy-in for referring patients to the screening clinic. Other challenges include complex reimbursement and documentation processes, design and implementation of patient tracking software options and education of insurance providers. Conclusion: The development and implementation of our screening program has been a valuable learning experience. To date we have screened 21 patients, one of which was found to have a squamous cell lung cancer. While our program is still new, we expect our volumes to grow over the next year as we continue to market our program in the region directly to patients and PCPs. We anticipate that our patient and provider satisfaction scores for this program will be high due to the expertise of our thoracic oncology nurse practitioner.
Introduction: Previous studies have alluded to the beneficial effects of vitamin D, particularly with regard to cancer. Vitamin D has been suggested to decrease negative effects of cancer treatments, hinder growth of tumor cells and reduce overall inflammation. Therefore, making sure patients have sufficient vitamin D is highly recommended. Breast cancer is something heavily researched. It is of interest to see if the development of cancerous cells is hindered by appropriate supplementation of Vitamin D. Design: A retrospective study to bring attention to hereditary cancer along with potential causes of the development of cancer cells associated with insufficient Vitamin D levels. Methods: Our preliminary study searched to determine if there was a correlation between BRCA1 and BRCA2 mutation carriers and vitamin D deficiency/ insufficiency. Data was obtained from a community based oncology clinic and compared to data from a study from the same clinic in 2006. We tested 36 patients with BRCA1 and BRCA2 deleterious mutations, whereby 75% (27/36) of the patients had a Vitamin D level less than 30 ng/mL. Results: There was a correlation between vitamin D insufficiency with BRCA1 and BRCA2 deletions within this group of patients (n=2 deficient, n=25 insufficient, n=9 normal levels). The 9 patients with normal levels in this study averaged 38.9 ng/mL, which is significantly lower than the average literature level of 52 ng/mL (P < 0.05). Of the 20 patients with normal vitamin D levels (30-74 ng/mL), all had deletions within exonic regions. The majority of the locations of the deletions were premature truncations, where there were no intronic deletions found. Conclusions: We have shown a correlation of Vitamin D insufficiency and BRCA deleterious mutations. Out of the 36 patients studied with deleterious BRCA mutations, 27 of them has had insufficient vitamin D. Based on our findings, providers in our community need to be more vigilant in assessment and treatment of Vitamin D as this may impact the incidence of cancer in high risk patients. Recommendations: The possibility of reducing inflammation through normalizing vitamin D levels should be enough reason for primary care providers to screen everyone. There is the potential to prevent cellular damage that consequently could affect cell checkpoints, leading to the development of cancerous cells in high risk populations. Future work could include study of germline vs. somatic cells and the effect of vitamin D on the genetic integrity of the cells.
JL403 Advanced Practice and Improved Outcomes for Infusion Therapy Patients Experiencing ADRs
Kelly R. Young, DNP, ANP-C, AOCN®, Duke Raleigh Medical Center, Raleigh, NC, Emily Dill, ANP-BC, MSN, Duke Raleigh Medical Center, Raleigh, NC, Yuri Fesko, MD, Duke Medical Oncology for Wake County, Duke University, Durham, North Carolina, and Lindsay MacDiarmada, MHA, Duke Raleigh Hospital, Raleigh, NC Objective: Our cancer infusion room treats sixty patients per day. Infusions include complex chemotherapy, monoclonal antibodies, and research pharmaceuticals. The high volume of infusions and the complexity of the regimens has led to increasing numbers of adverse drug reactions (ADR) or "allergic responses". This has been primarily due to anaphylactic and anaphylactoid reactions. Most chemotherapy reactions are true allergic reactions. They occur within minutes of the start of an infusion (Lenz, 2007; Zanotti & Markman, 2001) . Anaphylactoid reactions can occur within minutes to hours and are impossible to distinguish from serious reactions (Vogel, 2010) . ADRs complicate 5-10% of infusions. ADRs account for increased morbidity and mortality in both chemotherapy and in monoclonal antibody infusions (Gobel, 2007) . By placing an advanced practice provider (APP) in the infusion room, we anticipated better outcomes for patients experiencing ADRs. We hoped to prevent life threatening ADRs and to prevent the transfer of care to the emergency department. Methods: A retrospective analysis of 2016 events labeled as "allergic reactions" was completed. There were ADRs that lead to trans-fers to the emergency department. These ADRs were graded as a "unsafe condition" or nonevent to a "harmful" condition, or one that was temporary and required escalation in the level of care. An APP was placed in the infusion center. The APP was the "first responder" to reaction. The APP managed allergic reactions to prevent escalation of reactions and care. Results: The addition of the APP prevented escalating reactions that would have otherwise resulted in transfer to the emergency department. Prompt assessment and intervention led to significant decreased numbers of allergic events. While final numbers are pending, initial analysis translated into cost savings for the Center and the patients. Conclusions: An APP can influence the outcome of a ADR for staff and patients if available and prepared. The APP can help staff and patients navigate beyond the "standing" reaction order set when it is no longer helpful. The APP provides physical assessment skills and interventions that de-escalate the ADR both physically and fiscally. Recommendations: 1. APPs should routinely update themselves on the management of allergic reactions. 2. Every infusion center should be staffed with a APP who is knowledgeable about the therapies being given in the room and how to manage acute reactions. 3. APPs should be familiar with available supplies and be ready to deal with an allergic reaction from the moment an infusion is initiated.
JL404 An Academic Cancer Center's Approach to Observation Management Services
LaKeisha Day, PA-C, Anayo Mbadugha, PA-C, Sunil Sahai, MD, Kimberly Tripp, MBA, BSN, RN; University of Texas MD Anderson Cancer Center, Houston, TX Aim: To highlight an academic cancer center's approach to providing comprehensive care by utilizing a short-stay outpatient observation unit. Background: The Clinical Decision Unit (CDU) is a 16 bed observation unit that focuses on problem-based patient symptom management in collaboration with the primary oncology services. Design: Staffing-The CDU is staffed continuously by two Advanced Practice Providers (APPs), scheduled in alternating 12 hour shifts, with an on-call medical director for clinical and operational support. The APPs are from two existing programs that provide various inpatient and procedural services throughout the hospital. Intake/Placement-While the emergency center is the primary entry point for patients being placed in the CDU, outpatient clinics and procedural areas also request placement into the unit. The requesting service or designee makes the request for observation based on the clinical presentation at the time of the recommendation and medical necessity. Services-Once placed in the CDU, the APPs perform an initial assessment followed by patient care planning, including, a problemfocused history and physical, medication reconciliation, order management, expedition of consulting services or diagnostic exams and therapeutic procedures, where applicable. The APPs assess the patients every four to six hours to evaluate and document interim progress and make decisions on disposition. Findings: Placement Diagnoses-Patients placed in the CDU present with symptoms that are suitable for observation management and are at different phases of oncologic treatment. The most common diagnoses are: pain (categorized as pain of any kind), nausea/vomiting, anemia, and dehydration. Primary Service Utilization-A number of different primary oncology and surgical services populate the CDU. The top 5 services that house patients in the CDU are medical oncology services that provide treatment for solid tumor patients. Disposition Outcomes-From August 2015-June 2016, nearly 80% of patients placed in the CDU were discharged home versus those requiring an inpatient admission. Summary: Since its commencement in November 2014, the CDU has been a beneficial addition to patient care services by managing symptoms of patients who would have previously been hospitalized or forced to wait for a clinic appointment. The CDU provides dedicated, problemfocused care to patients, while emphasizing continuity of patient care by collaborating with primary oncology teams, to provide outpatient observation management services that aims to not only avoid an unnecessary hospital stay, but to also bridge any necessary care between scheduled clinic visits. Jean A. Ridgeway, DNP, APN, NP-C, AOCN®, and Kaitlin Caponi-Holcomb, MSN, FNP-BC; University of Chicago Medical Center, Chicago, IL Purpose: To develop and evaluate the use of a comprehensive educational checklist for allogeneic stem cell transplant patients, that will be used by all members of the HSCT interdisciplinary team (IDT) during initial transplant hospitalization.
Significance: Allogeneic hematopoietic stem cell transplantation (HSCT) has emerged as a unique treatment modality. 50% of patients who received an allogeneic HSCT and caregivers report feeling inadequately equipped to manage post-discharge plan of care. HSCT patients remain one of the most fragile populations to prepare for discharge and present a challenge to be information ready. It is essential that interdisciplinary team (IDT) members prepare the HSCT patients with the education needed in order to deal with the overwhelming task involved during and after hospitalization. Healthcare checklists have produced dramatic, sustained gains in patient safety and quality of care. Checklists provide an ideal way to comply with standards of evidence based care and promote good communication among IDT members. Sample/Methods: IDT members of the adult HSCT program and a convenience sample of adult HSCT patients undergoing their first allogeneic stem cell transplant. The project was conducted by educating IDT members on how to use the checklist, encouraging use of the checklist as documentation of education while patients were hospitalized. Then evaluating the completed checklists items at discharge. A pilot study. Results: IDT educated (n=82), 22 patients consented, 20 participated (2 patients did not receive transplant). Average completion of checklist was 76%. Self-care domain (95%) was most documented domain, while adapting to posttransplant lifestyle (62%) was the least. IDT members with a nursing educational background accounted for 95% of all documentation completed. Conclusions: Checklists were completed by various IDT members throughout hospitalization of HSCT patients. IDT members often assume that "other" team members are completing education; however, if there is a lack of documentation there is no reliable source to verify completion of the education. Documentation was viewed as a "burden" by IDT members leading to documentation "fatigue/burnout". Implications for Practice: IDT checklists can only be as "interdisciplinary" as those who participate and document. Inherit care complexity of patients with multiple "teams", can be streamlined with a checklist. This checklist allows for the IDT members to engage in meaningful discussions with patients and caregivers about their plan of care. From this discussion, that goes 
JL408 Decreasing Venous Thromboembolism in Patients With Hematologic Malignancy Through Implementation of Clinical Practice Guidelines -A Quality Improvement Project

Karley M. Trautman, DNP, ANP-BC, and Chelsey Boggs, MS, AG-NP-BC; Blood Cancer and Bone Marrow Transplant Program, University of Colorado Anschutz Medical Campus, Aurora, CO
Background: Venous thromboembolism (VTE) is a highly prevalent complication in patients with cancer with reported incidence rates ranging between 8-19% (Khorana, Dalal, Lin, & Connolly, 2013) . Patients with VTE have at least a 2-fold increase in mortality compared to those without VTE, even after adjusting for staging (Khorana & Connolly, 2009 ).
Because of this, there is a justifiable need to decrease the incidence of VTE by standardizing practice to align with the current evidence-based practice (EBP) guidelines while simultaneously not increasing bleeding risk in patients with thrombocytopenia. Objective: The aim was to decrease the rate of acute VTE and recurrent VTE in adults with hematologic malignancies by standardizing the risk assessment, use of prophylactic anticoagulation, and treatment duration of therapeutic anticoagulation without increasing bleeding risk in the inpatient and outpatient clinical settings at the University of Colorado Blood Cancers and Bone Marrow Transplant Program. Intervention/Methods: The National Comprehensive Cancer Network (NCCN) VTE guidelines were used to develop a clinical practice guideline addressing standard VTE risk assessment, appropriate use of prophylactic anticoagulation, and standardized duration of therapeutic anticoagulation. Data was collected for 12 months prior to the implementation of the guideline and for 24 month post-implementation. Results: Overall VTE rates decreased from 13.99% to 6.18%, recurrence rate decreased from 42.5% to 20.93%, and bleeding risk improved from 18.52% to 7.06%. Percentage of inpatients receiving prophylactic anticoagulation increased from 25.2% to 42.58% and eligible outpatient myeloma patients receiving prophylaxis increased from 82.76% to 96.97%. Conclusions: Standardization and development of clinical practice guidelines improved VTE incidence and recurrence rates and improved overall adherence to EBP guidelines. Routine prophylactic anticoagulation did not increase bleeding risk in this patient population. Implications for Practice: EBP guidelines aid providers in making sound clinical decisions regarding the management of VTE in patients with hematologic malignancies. Quality improvement projects have a vital role in effective translation of EBP in practice. Data updated at time of publication of this JADPRO issue.
JL409
Development of An Evidence-Based Scorecard to Assess Provider Adherence to Gastrointestinal Toxicity Management
Carrie T. Stricker, PhD, RN, Carevive Systems, Inc., Miami, FL, Debra Wujcik, PhD, RN, FAAN, Carevive Systems, Inc., Miami, FL, June Eilers, PhD, APRN-CNS, BC, FAAN, University of Nebraska Medical Center, Omaha Division, Omaha, NE, Beth Faiman, PHD, MSN, APRN-BC, AOCN®, Cleveland Clinic, Cleveland, OH, Amy Goodrich, CRNP, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, Mary Pat Lynch, MSN, CRNP, AOCNP®, Abramson Cancer Center, Hospital Objective: Gastrointestinal toxicity (GIT) is associated with targeted therapies in cancer treatment. GIT can lead to diminished treatment adherence and poor quality of life. It is among the top causes of emergency room visits and hospitalizationstargeted by value-based payment models including the Oncology Care Model (OCM). Evidence for the prevention and management of GIT exists. Yet, what constitutes "good" versus "poor" GIT management (GITM) has not been defined in a measureable way; little is known about how evidence based guidelines are applied in the realworld practice environment. Because patients on oral oncolytics are typically seen less frequently in the clinic, health care providers are not routinely observing patients. The processes for patient reporting of symptoms and clinician triaging, evaluating, and managing GIT are inconsistently documented in the patient's health record. Thus, the effect that real world GITM practices have on patient outcomes is unknown. This formative work is the initial part of a larger study to understand real world GITM by defining quality management. Next, the study will quantify provider adherence to these quality management standards. Methods: An expert oncology nurse researcher led a team of 5 oncology advanced practice nurses (OAPN) in the development of an instrument to define quality GITM. The GITM ScoreCard (SC) was developed through processes that included literature review and consensus development for ideal management where evidence gaps existed. The OAPNs developed literature review results of GITM evidence-based practices using a standardized template. The nurse researcher reviewed the literature review results for consistency, flagging sections requiring further discussion. Consensus was achieved through two scheduled sessions with the entire group. Results: An evidence-based SC was developed that can be used in any clinic MEETING ABSTRACTS setting to assess GITM practices. The SC includes four symptoms: Diarrhea, Constipation, Mucositis, and Nausea/Vomiting. GITM practices include 1) prevention, 2) assessment 3) pharmacologic and non-pharmacologic management by toxicity grade, and 4) other. Scoring for each response is 1) Never, 2) Occasionally, < than half time, 3) Most of the time, > half time, and 4) Always. Conclusion: Development of evidence-based GITM SC is the first step in understanding real world GITM. Provider self-assessment using the SC will provide the first known documentation of provider adherence to evidence-based GITM. Recommendations: The GITM SC has the potential to be used in any clinic setting that desires to evaluate and improve the quality of their current GITM practices.
JL410
Identification of Continued Educational Gaps Among Oncology Nurses Treating Patients With Pancreatic Cancer: A Case for Further Education
Nina N. Grenon, DNP, AOCN®, Dana-Farber Cancer Institute, Boston, MA, and Patricia M. Repetto, M.Ed, CHCP, Medscape Oncology, New York, NY Introduction/Background: In recent years, the treatment paradigm for management of advanced pancreatic cancer has changed dramatically. Because oncology nurses are on the front line of care for patients with pancreatic cancer, we sought to evaluate their knowledge and competence in the care of patients with advanced disease and the impact of casebased education on narrowing gaps in clinical practice. Materials and Methods: An online educational program designed as a video roundtable discussion between nurses and tailored to a nursing audience was posted on Medscape Oncology January 13, 2016, and ran until March 8, 2016 (http://www.medscape. org/viewarticle/855566). Educational efficacy was determined by using each learner as their own control and comparing each participant's responses to a series of 4 questions posed before exposure to educational content (pre-assessment) with his/ her responses the identical questions posed after exposure to the educational content (post-assessment). Responses of participants who answered all pre-and post-assessment questions during the study period were included in the analysis. McNemar's chi-square test was used to assess differences from pre-to post-assessment responses for all questions combined. Cramer's V was used to estimate the strength of the association between pre-and post-assessment test scores. P values are shown as a measure of significance with P<.05 indicated statistical significance. Results: Nearly 13,000 nurses participated in the activity, of which 1896 qualified for inclusion in this study. Participation in this educational program resulted in a medium effect size (Cramer's V = 0.189; P < .05). Significant improvements included (Figure 1 ; all P < .05):
• A relative 81% improvement in knowledge related to the management of pancreatic insufficiency in patients (P < .05) • A relative 46% improvement in comprehension of the role palliative care has in the management of patients with advanced pancreatic cancer (P < .05), although nearly 30% still selected incorrect responses after the activity • A relative 31% improvement in recognition that one of the most common treatment-related adverse effects of nanoliposomal irinotecan is neutropenia (P < .05) • A relative 36% improvement in distinguishing differences in the adverse effect profiles of nabpaclitaxel with gemcitabine versus gemcitabine monotherapy (P < .05) Conclusions: This study identified ongoing educational gaps that suggest development of additional education is needed to improve oncology nurse knowledge and competence in the management of pancreatic cancer, especially in recognition of the value of supportive and palliative care as well as recognition of distinguishing characteristics of the adverse effect profiles of evidence-based regimens.
JL411 Implementation and Evaluation of an Influenza Adherence Toolkit in Allogeneic Bone Marrow Transplant Recipients
Tracy Krimmel, DNP, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Susan M. Schneider, PhD, RN, AOCN®, FAAN, Duke University School of Nursing, Durham, NC, Rajat Bannerji, MD, PhD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, and Maribel Borysyuk, PharmD, Walgreens, Dallas, TX Background: The incidence of influenza in hematopoietic stem cell recipients is 7-35% with a 15-35% mortality rate (Shah et al., 2012) . Vinograd et al.
(2014) reported a 48% compliance rate in influenza vaccinations. In our NCI-designated cancer center, the baseline adherence rate with influenza vaccination in the post-allogeneic setting was 62.5%. Methods: This project was a pre-test post-test quality improvement project to determine patient knowledge and vaccination adherence rates following implementation of the influenza adherence toolkit. The intervention included: 1) Pre and Post screening survey, 2) The toolkit which includes an influenza disease education pamphlet and financial incentive, and 3) reminder letter. Results: There were 48 eligible patients for the project, 32 completed the prescreening questionnaire (66.7%). The results showed overall adherence rate for 2015-2016 to be 88.5%, compared to a baseline vaccination rate of 62.5%. Findings also revealed a strong association between provider recommendations and influenza vaccination adherence, 23 of the 24 (96%) patients who had a provider recommend receiving the flu shot did receive it (p=.009). Conclusion: Findings showed that implementation and evaluation of an influenza toolkit in allogeneic hematopoietic recipients improves adherence rates. Consistent with previous studies, there was a strong association between provider recommendation and obtaining the vaccination.
JL412
Management of Endocrinopathies Associated With Nivolumab and Ipilimumab Combination Therapy in Solid Tumors
Marianne Davies, DNP, ACNP, AOCNP®, Yale University School of Medicine, New Haven, CT, Laura S. Wood, RN, MSN, OCN®, Cleveland Clinic, Cleveland, OH, Krista Rubin, MS, FNP-BC, Massachusetts General Hospital, Boston, MA, Kathleen Madden, NP, MSN, FNP-BC, AOCNP®, APHN, New York University, New York, NY, Laura Brennan, NP, AOCNP®, UC Davis Medical Center, Sacramento, CA, Nathan Dahl, PharmD, RPh, Mayo Clinic, Rochester, MN, Dana Walker, MD, MSCE, Bristol-Myers Squibb, Princeton, NJ, Paul Gagnier, PhD, MD, Bristol-Myers Squibb, Princeton, NJ, Xuemei Li, MD, Bristol-Myers Squibb, Princeton, NJ, and Lisa Kottschade, APRN, MSN, CNP, Mayo Clinic, Rochester, MN Background: Combination therapy with nivolumab (NIVO) and ipilimumab (IPI) is approved for the first-line treatment of advanced melanoma (MEL). Recent phase 1 studies have also shown promising efficacy with NIVO+IPI in patients (pts) with nonsmall cell lung cancer (NSCLC) and metastatic renal cell carcinoma (RCC). With NIVO+IPI, select adverse events (ie, immune-related AEs) most commonly affect the skin, gastrointestinal tract, endocrine organs, and liver. Unlike other immunerelated AEs, endocrinopathies can persist despite discontinuation or completion of therapy. Here, we review endocrine select AEs associated with NIVO+IPI in solid tumors and provide practical guidance regarding their management. Methods: Safety data were included from phase 2 (CheckMate 069) and phase 3 (CheckMate 067) studies for MEL, and phase 1 studies for NSCLC (CheckMate 012) and RCC (CheckMate 016). Data are reported for NIVO 1 mg/kg + IPI 3 mg/kg Q3W x 4 for MEL, NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W for NSCLC, and NIVO 3 + IPI 1 or NIVO 1 + IPI 3 mg/kg Q3W x 4 for RCC, followed by NIVO Q2W. Pts were treated until disease progression, unacceptable toxicity, or withdrawal of consent. Results: In pts with MEL who received NIVO+IPI combination therapy, ~32% experienced any endocrine select AE, of which 5-6% were grade 3-4 (Table) . Endocrine select AEs of any grade occurred in 21% of pts with NSCLC, in 28% of pts with RCC who received NIVO 3 + IPI 1 mg/kg, and in 43% of pts with RCC who received NIVO 1 + IPI 3 mg/kg. The most common treatment-related endocrine select AEs across tumor types were hypothyroidism, hyperthyroidism, and adrenal insufficiency. Median time to onset for endocrine select AEs was 6 weeks in MEL. Only 2-3% of pts discontinued due to treatment-related endocrine select AEs. Some pts (typically those with lower grade AEs) can continue NIVO if the AEs were related to IPI. Persistent or worsening fatigue, headaches, and nausea are common symptoms, and may be associated with hypophysitis. Baseline labs (including thyroid-stimulating hormone) should be performed. MRI with pituitary cut can be used to evaluate potential immune-mediated hypophysitis. Pts with thyroid dysfunction need symptomatic management and thyroid hormone replacement, and those with adrenal insufficiency may require long-term glucocorticoid replacement. Implications: Endocrine select AEs are manageable with established treatment algorithms. Given the unique nature of endocrine AEs, early identification is critical and a multidisciplinary team approach is required to effectively manage these pts. Center, Sacramento, CA, Dana Walker, MD, MSCE, Bristol-Myers Squibb, Princeton, NJ, Xuemei Li, MD, Bristol-Myers Squibb, Princeton, NJ, Paul Gagnier, PhD, MD, Bristol-Myers Squibb, Princeton, NJ, and Laura S. Wood, RN, MSN, OCN®, Cleveland Clinic, Cleveland, OH Background: Nivolumab (NIVO) and ipilimumab (IPI) combination therapy is approved for the first-line treatment of advanced melanoma (MEL), and recent phase 1 studies have shown promising efficacy in non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (RCC). NIVO+IPI is associated with a higher frequency of treatment-related AEs compared to monotherapy, with select AEs (ie, those with an immune-related etiology) in the skin and gastrointestinal (GI) tract being the most common. Here, we review the incidence of GI select AEs in patients (pts) treated with NIVO+IPI and present practical guidance regarding their management. Methods: Safety data were included from phase 2 (CheckMate 069) and phase 3 (CheckMate 067) studies for MEL, and phase 1 studies for NSCLC (CheckMate 012) and RCC (CheckMate 016). Data are reported for NIVO 1 mg/kg + IPI 3 mg/kg Q3W x 4 for MEL, NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W for NSCLC, and NIVO 3 + IPI 1 or NIVO 1 + IPI 3 mg/kg Q3W x 4 for RCC, followed by NIVO Q2W. Pts were treated until disease progression, unacceptable toxicity, or withdrawal of consent. Results: In MEL pts treated with NIVO+IPI, ~48% experienced any grade GI select AEs; 15-20% experienced grade 3-4 AEs, with the most common being diarrhea and colitis (Table) . Any grade GI select AEs occurred in 23% of pts with NSCLC, in 26% of pts with RCC who received NIVO 3 + IPI 1 mg/kg, and in 45% of pts with RCC who received NIVO 1 + IPI 3 mg/kg. To effectively manage GI AEs, pts need to report all GI symptoms (e.g., increased stool frequency, loose consistency, abdominal cramping, and bloody diarrhea) promptly to their oncology healthcare provider. Pts with diarrhea should undergo stool testing to rule out infectious causes. GI AEs can progress rapidly, and thus healthcare providers should initiate treatment at the first sign of symptoms (corticosteroids for pts with persistent grade ≥2 AEs) even before stool testing results are available, in order to prevent serious complications of intestinal inflammation such as bowel perforation. Implications: Across solid tumor types, GI select AEs are among the most commonly reported side effects in pts who receive NIVO+IPI therapy. With early recognition and intervention, serious complications from GI select AEs may be minimized using established management guidelines involving immune modulating medications. Pt education and frequent follow-up are also key to minimizing serious complications from these AEs. Introduction: HCC is the fifth most common malignant neoplasm in men and ninth most common in women worldwide. Although the incidence of HCC in the United States is rare, the incidence of this particular cancer is rising secondary to the increasing prevalence of hepatitis B, hepatitis C, alcohol abuse, and non-alcoholic steatohepatitis (NASH). In the setting of liver transplantation exclusion, surgical resection remains the gold standard for patients with resectable HCC. However, most patients with HCC present with unresectable tumors in the background of chronic liver disease. Furthermore, the underlying liver disease, such as cirrhosis, is a major confounding factor that contributes to its chemotherapy-resistant characteristic. In patients with unresectable HCC in the background of a normal liver, however, systemic chemotherapy has been shown to be somewhat effective, but its role in the neoadjuvant setting remains controversial. Additionally, transarterial chemoembolization (TACE) is an effective locoregional approach used to downsize tumors prior to surgical resection. Can the combination of systemic chemotherapy and TACE be utilized in the neoadjuvant setting to potentially preserve the surgical option for this patient population? We present a case study that details the unique role of systemic chemotherapy and TACE in downstaging patients with large and unresectable HCC in the background of a normal liver to resectability. Description: Case: 60-year-old gentleman with a solitary 17 cm left liver mass, encroaching the right liver with displacement of the main portal vein and involvement of the right hepatic vein, biopsy-proven HCC. He had no risk factors for HCC (negative for hepatitis B & C; nondrinker). The patient was deemed unresectable at that time and was dispositioned to systemic chemotherapy and TACE with the goal of down-sizing the tumor for surgical resection with good margins. Conclusion: In patients with initially unresectable and large HCC in the background of a normal liver, the role of systemic chemotherapy and TACE should be considered as a neoadjuvant treatment modality to convert the patient for surgical resection. Advanced practice providers play a vital role in the process of the treatment planning for each patient. We hope to provide an alternative and effective treatment plan for patients with HCC in the background of normal liver while preserving the surgical option to patients who were deemed initially unresectable. The patient underwent a parathyroidectomy with an en bloc resection left lobectomy, excision of sternocleidomastoid muscle, and a few surrounding lymph nodes. Pathology revealed parathyroid carcinoma. Given the malignancy findings, a staging CT scan followed which did not reveal metastasis. She was evaluated every 6 months with a calcium and PTH level. Her levels remained normal until 2 years post-operatively when her calcium was elevated at 11.9 and subsequent Neck CT revealed cervical adenopathy. She was then referred to a high-volume cancer center where biopsy confirmed recurrent disease in the left neck and superior mediastinum, and she underwent lymphadenectomy. Unfortunately, she later presented with metastasis to the liver. This case will be presented to elucidate the unique features of parathyroid carcinoma along with its diagnosis and management. Conclusion: Parathyroid carcinoma is rare, but it is vital for APPs to be knowledgeable of its appropriate evaluation and management as recurrence and persistent disease can be a problem in more than 50% of patients. It is important to be well-informed in order to manage, counsel, and refer patients appropriately. Much work is needed towards formulating a TMN staging system to guide treatment. Accurate diagnosis, pathological evaluation, and surgical documentation is vital to long term development of a staging system.
JL415 Nurses Championing Exercise in Survivorship Care Clinic Visits
JL417 Performance Improvement Continuing Medical Education (CME) for the Advanced Practice Provider in Oncology
Kelly R. Maldonado, MPAS, PA-C, Maura Polansky, MS, MHPE, PA-C, Jessica Eno, MS, PA-C, Leah Theriot, MPAS, PA-C, Carolyn Zawislak, MPAS, PA-C, and Steven H. Wei, MS, MPH, PA-C; University of Texas MD Anderson Cancer Center, Houston, TX
Background: Performance improvement (PI) is one of the newest CME learning formats designed for providers to evaluate and make changes to their clinical practice. In 2014, The National Commission on Certification of Physician Assistants (NCCPA) implemented a change in the recertification process to include PI as part of the required CME category 1 credits. Following the end of a ten-year cycle, physician assistants must have at least 40 category 1 PI-CME credits. PI-CME is different from other category 1 activities as it involves a structured and systematic three-stage approach by which evidenced based performance measures are used to help providers identify areas of improvement in their clinical practice. In this three-stage process, the provider must first assess their practice by comparing it directly to an evidence based performance measure. The provider then must analyze and consider the results of the data for areas of improvement and identify one or more strategies for improvement. After implementing a strategy and collecting additional data following the implementation, the provider must finally reflect on the results. The advantage of PI-CME is that it can be developed for any subspecialty of practice. It can essentially address any process related to health care delivery. Purpose: To update physician assistants of the PI-CME requirements for certification maintenance and to provide advanced practitioners an overview of the stages of developing a PI-CME activity as it relates to improving patient care in the oncology practice setting. Description: We describe 3 PI CME activities developed by physician assistants at the University of Texas MD Anderson Cancer Center to be used by physician assistants in the fields of medical, surgical, and radiation oncology. These activities were developed by and for physician assistants to address specific patient care issues related to the care of the oncology patient such as accuracy in communicating patient hand offs, proper monitoring of patients receiving chemotherapy, and ensuring appropriate follow up evaluation after completion of radiation therapy. Conclusion: PI-CME is a structured tool that is relevant to all advanced practice providers, not only physician assistants, and is an active application of learning which ultimately leads to improved patient outcomes. PI-CME is applicable to any subspecialty of practice, including the specialized fields of oncology.
JL418 Primary Polycythemia Vera: Advances in Diagnosis and Treatment
Kathy Leonard, MA, ACNP-B, ANP-B, ANP-BC, AOCNP®, New York University Clinical Cancer Center, New York, NY
Purpose: The purpose of this poster presentation is to educate advanced hematology/oncology practitioners how to diagnose, evaluate thrombotic risk, manage and treat patients with primary polycythemia vera. Background: Primary polycythemia vera is a clonal stem cell disorder characterized by erythrocytosis, as well as leukocytosis and thrombocytosis. It is a Philadelphia chromosome negative subtype of the myeloproliferative neoplasms. The age of diagnosis is usually in the sixth decade and is rarely seen in individuals under the age of thirty. The condition was first described in the late 1800s, and it wasn't until 2005 that a mutation of the JAK2 (Janus kinase 2) gene was identified as playing a role in this disease. Polycythemia vera may result in life threatening thrombotic events, progression to myelofibrosis and acute myeloid leukemia. The primary treatment is aspirin and thera-peutic phlebotomy with platelet lowering in select patient populations. The identification of the JAK 2 V617F mutation has led to a more definitive diagnosis and has made way for the use of JAK inhibitors. Discussion: Treatment of polycythemia vera is aimed at prevention of life threatening thromboembolic events through careful risk stratification, identification and monitoring of side effects of pharmacological agents and early identification of disease progression to myelofibrosis and acute myeloid leukemia. Implications for Advanced Practice: It is very important that advanced hematology/oncology practitioners have a strong knowledge and understanding of the diagnosis, management and treatment of this disease. The advanced practitioner has a pivotal role in treatment and management of those with polycythemia vera.
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Recognizing Background: The contributions of advance practice providers (APPs) to an oncology practice are complex, and it can be challenging to discern and measure how their unique contributions are impacting their practice. Two terms, productivity and value, are used to measure contributions. APPs should have a clear understanding of their practice's definition of these terms and their expectations for evaluation of APP contributions, because when APPs' contributions are valued, their job satisfaction and team productivity are likely to improve. In addition, proper documentation of the quality and cost-effectiveness of the care provided by the APP is crucial to the overall success of the practice and to ensuring that APPs continue to contribute and thrive in the oncology arena. Methods: We surveyed APPs and nurses to assess whether and how their contributions were being measured. An overview of the tools currently used in clinical practice is also provided. Results: The survey had an approximately 10% response rate and was answered by 59 APPs (who constituted 80% of the respondents). APP productivity was formally (36%) or informally (42%) measured for the majority of respondents, but only 25% believed that their productivity was being measured accurately. Relative value units (RVU, 39%) and hours per patient day (19%) were used; however, most APPs considered RVU an ineffective measure of both productivity and value.
Value was not measured for many respondents (46%), and 29% did not know whether their value was being assessed. This is despite the fact that respondents spent an average of 19.8 hours per week on value-added activities that improve patient care and satisfaction. Conclusions and Recommendations: The crux of the issue is whether APPs can realistically gauge their value and contribution to a practice if the care they provide for their patients is not accurately assessed. APPS should ask whether they feel valued by their practice, patients, and physicians and how this impacts their overall job satisfaction. These answers could be important for retention of APPs and should be used to initiate conversations to increase awareness of APP contributions to the practice. We recommend that APPs consider tracking their work activity and the time it takes to complete tasks, especially those that are non-billable services. APPs should also consider asking the practice to review productivity of the team before and after the APP joined the practice to raise awareness of their contributions.
JL420 Redesigning How We Communicate Important Safety Information (ISI) Using the Universal Patient Language
Elizabeth M. Chebli, PharmD, CMPP, Bristol-Myers Squibb, New York, NY Background: The Universal Patient Language (UPL), is a set of resources developed by Bristol-Myers Squibb, to help communicate with patients about complex topics. At the core of the UPL are seven foundational principles. BMS applied these principles to create a UPL version of Important Safety Information (ISI). Before and during oncology treatment, patients need to understand the treatment's risks, benefits, and other important information on how to take the medicine and drug interactions. Pharmaceutical companies communicate these details through the ISI. Traditionally, ISI is developed within a fixed, text-only template working within specific FDA guidance. The goal was to redesign how ISI is communicated by applying the UPL, to make it more inviting for patients to read, and potentially easier to understand. We started with a specific drug's ISI, with the goal of using the output as a starting point for redesigning ISI for other BMS medicines. Method: Co-creation, the core method of applying the UPL, is a service-design technique that brings together multiple perspectives to reimagine and build new materials. To design a UPL version of ISI, a co-creation session was held with patients, communication experts and BMS employees with knowledge of the relevant regulations. Together, participants identified ways to improve ISI, and built rapid prototypes of what a UPL ISI could look like. The prototypes that emerged were further refined and validated with patients and BMS stakeholders. Results/outcome: The first UPL ISI was included in patient-facing brochures and released in 2015. The UPL redesign is much more visual, using whitespace, icons and simpler language. It also includes additional information, based on what patients said was important to them at the co-creation. To date, three different BMS products have implemented the UPL ISI. Enterprise templates and usage guides for ISI have also been created for other brands looking to use the UPL ISI. In small-scale testing, participants consistently responded positively to the design's ability to help in identifying the most relevant information, and communicating the importance of following the instructions. These effects were stronger for respondents who had a treatment-appropriate diagnosis. In qualitative interviews, patients were overwhelmingly receptive to the new design-one patient said "I would put it on my fridge". Implications: The UPL tool can be used in oncology to help make complex information easier for patients to understand. The UPL ISI is just one application and other case studies and tools can be found on UPL.org.
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Review of a Genetic Risk Assessment Delivery Model in a Private Community Oncology Practice
Doreen Grzelak, NP-C, CBCN, MSN, AOCN®, Virginia Cancer Specialists, Washington, DC
According to the Oncology Nursing Society (ONS), part of the advanced practice nurse (APN) role is to provide genetic and genomic care to individuals in conjunction with expert providers (ONS, 2012) . This is a review of a genetic risk assessment program in a private community oncology practice. The delivery model utilized includes physicians, an APN and a genetic counselor. Data was reviewed retrospectively from the inception of the program in 2011 through 2015. In addition to reviewing the number of patients seen, data was analyzed to determine the most frequent diagnosis, as well as results of genetic testing. We found that there was a need for this service for current patients in our practice and affected individuals in the community, as well as individuals in the community who were unaffected but had a family history of cancer. In 2014 and 2015 over one half of those seen were referred from outside of the practice. As expected, the most frequent diagnosis of those counseled was breast cancer. The second largest group was unaffected individuals seeking counseling based on family history. Additionally, as expected with the advent of panel testing, our results revealed an increase in variants of uncertain significance (VUSs).
As the knowledge of genetic information continues to evolve, changes to guidelines for testing of individuals with cancer continues to expand. We anticipate the demand for genetic counseling to increase. The use of qualified non-genetic counselors in conjunction with genetic counselors in private community oncology practice is a delivery model that provides a needed service for oncology patients and their families. As a result, advanced practitioners (APs) will need to find methods to remain updated on recommendations for genetic risk assessment to provide counseling or refer patients appropriately. ® from the University of Pittsburgh School of Nursing and funded by the National Cancer Institute (1 R25 CA148050-01A1). The course is designed specifically for Nurse Practitioners (NPs) in their first year of oncology practice paired with an on-site mentor (physician, nurse practitioner or physician assistant). The 5th module in the course focuses on Self-Care and Professional Development. The purpose of this study was to examine the impact of the ONc-PoWER course on the professional development of Nurse Practitioners 6 months or more after course completion. Method: NPs and mentors completed the course over 4-6 months. As a follow up measure 51 NPs were sent a survey regarding their professional activities since the completion of the ONc-PoWER course. There were 9 items with Likert scale responses of: 3) To a great degree, 2) Somewhat, 1) Not at all. Results: There were n=24 (41%) response. All but one were female with 23 white/Caucasian and 1 black/African American. See table. Conclusion: The ONcPoWER course was effective in encouraging Oncology Nurse Practitioners in their professional development. Most effective was utilization of evidence for practice; least effective was the translation of evidence for other health care providers. This is an ongoing analysis. Implications: Future renditions of the course will include a stronger emphasis on scholarly publications and the translation of research findings and evidence. MEETING ABSTRACTS tically significant (no multiplicity correction). Loratadine was associated with fewer AEs than naproxen, and fewer patients discontinued loratadine. See table for additional results. Conclusions: Levels of all-grade bone pain from AE reporting were comparable in the naproxen, loratadine, and no prophylaxis groups, but there was a consistent trend toward lower pain with naproxen and loratadine, particularly when analyzing measures of patient-reported pain. Loratadine was better tolerated than naproxen.
Recommendations: Given its ease of administration, tolerability, and potential benefit, treatment with daily loratadine to help prevent bone pain should be considered for patients receiving chemotherapy and pegfilgrastim.
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Symptoms Treatment strategies include dexamethasone for edematous and symptomatic BM, and anticonvulsants for seizure prevention. It is important to distinguish the effects of new BM from radiotherapy-induced radionecrosis, as this can present as an edematous growing mass on imaging. Likewise, some ALKi side effects can be difficult to differentiate from symptoms of new BM (e.g. visual disturbances, nausea/vomiting). The side effects of treatments for symptoms must also be managed; strategies include minimizing/tapering corticosteroid doses and adjustment of anticonvulsants based on altering symptoms. Recommendations: As soon as symptoms of BM are recognized, primary oncology healthcare providers should reach out to neurosurgeons/neurologists/neuro-oncologists and CNS radiotherapists as appropriate. ALK+ NSCLC patients require regular interval followups for focused neurologic assessment with recent imaging results. Ophthalmologists should be consulted to manage visual disturbance. Physical therapy may help manage aerobic incapacity, weakness, balance/coordination, and visual-perceptual impairment. Initiation of BM treatment, including switching ALKi therapy, should be considered (it is recommended that ALKis are held during WBRT). Conclusions: Early identification of CNS progression has the potential to improve ALK+ NSCLC patient prognosis by providing an opportunity for rapid and timely intervention. Repeated treatment of CNS disease with ALKis/SRS is becoming the new standard of care, with ALKis preferred over WBRT.
Background:
The decision to prescribe a packed red blood cell (PRBC) transfusion in patients with chemotherapy-induced anemia includes assessment of clinical features such as the patient's cancer type and treatment regimen, severity of signs and symptoms of anemia, and presence and severity of comorbidities. Here, we sought to examine contemporary transfusion practices in patients receiving myelosuppressive chemotherapy for nonmyeloid cancer. Methods: Eligible patients were ≥18 years of age, had nonmyeloid cancer, were receiving first-or second-line myelosuppressive chemotherapy, had baseline hemoglobin (Hb) ≤10.0 g/ dL, and were planned to receive ≥1 PRBC transfusion. Key exclusion criteria were receipt of an erythropoiesis-stimulating agent within 8 weeks prior to screening and/or chronic renal insufficiency. The study ran from 30-Sep-2014 to 31-Oct-2015. Data were collected from patients' medical records, laboratory values, and physician/provider questionnaires to determine considerations for transfusions. The proportions of primary clinical considerations leading to PRBC transfusions and 95% exact binomial confidence intervals (CIs) were estimated. Re- Note. CI = confidence interval; Hb = hemoglobin; PRBC = packed red blood cell; SD = standard deviation. a One patient was excluded, as the Hb concentration was measured after a PRBC transfusion. 
